Intellia Therapeutics (NTLA) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 286.5% versus a loss of 42.7%. Over five years, ORKA leads with a +137.5% price change compared with -91.0% for NTLA. Oruka Therapeutics is the larger company by market cap ($5.15 billion vs $1.69 billion), about 3.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTLA | ORKA |
|---|---|---|
| Share price | $12.04 | $77.85 |
| Market cap | $1.69B | $5.15B |
| 1-day change | +2.82% | -2.08% |
| YTD return | +30.26% | +162.29% |
| 1-year return | -42.71% | +286.49% |
| 5-year return | -91.03% | +137.46% |
| EPS (TTM) | $-3.35 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-105.43M |
| 52-week high | $28.25 | $115.52 |
| 52-week low | $7.95 | $21.66 |
| Distance from 52-week high | -57.38% | -32.61% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +91.94% | +99.10% |
| Average volume | 4.16M | 886.21K |
| Shares outstanding | 140.13M | 66.21M |
| Employees | 377 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 3.1 times larger than Intellia Therapeutics by market value ($5.15B vs $1.69B).
- ORKA has outperformed NTLA by 329.2 percentage points over the past year.
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
NTLA vs ORKA FAQ
Which is bigger, Intellia Therapeutics or Oruka Therapeutics?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.15B compared with $1.69B for Intellia Therapeutics (NTLA).
Which stock has performed better over the past year, NTLA or ORKA?
ORKA returned +286.49% over the past 12 months, compared with -42.71% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Intellia Therapeutics and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.